|
Atherosclerosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
We tested whether lobeglitazone, a new PPARγ agonist, might protect against atherosclerosis.
|
26363808 |
2015 |
|
Atherosclerosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
Macrophage lipid metabolism is transcriptionally regulated by peroxisome proliferator-activated receptor gamma (PPARγ), and its target gene fatty acid binding protein 4 (FABP4) accelerates the progression of atherosclerosis in mouse models.
|
25897794 |
2015 |
|
Atherosclerosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
We explored whether TNF-α could promote atherosclerosis by increasing the transcytosis of lipoproteins (e.g., LDL) across endothelial cells and how NF-κB and PPAR-γ were involved in this process.
|
24594319 |
2014 |
|
Atherosclerosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
In early lesions, PPARG was identified as a specific master regulator of the PCL-responsive atherosclerosis TF-regulatory network, whereas in mature and advanced lesions, the specific master regulators were MLL5 and SRSF10/XRN2, respectively.
|
24586211 |
2014 |
|
Atherosclerosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
Macrophage foam cell formation by oxidized low-density lipoprotein (oxLDL) is a key step in the progression of atherosclerosis, which is involved in cholesterol influx and efflux in macrophages mediated by related proteins such as peroxisome proliferator-activated receptor γ (PPARγ), CD36, PPARα, liver-X receptor α (LXRα), and ATP-binding cassette transporter A1 (ABCA1).
|
25010893 |
2014 |
|
Atherosclerosis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Peroxisome proliferator-activated receptor gamma-2 gene (PPARγ2) rs1801282 (Pro12Ala) polymorphism has been associated with lower risk of metabolic disturbance and atherosclerosis.
|
25159899 |
2014 |
|
Atherosclerosis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The Pro12Ala and C161T polymorphisms in peroxisome proliferator-activated receptor γ (PPARγ) have been shown to be associated with carotid artery atherosclerosis.
|
25096510 |
2014 |
|
Atherosclerosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
TZDs including pioglitazone, rosiglitazone and troglitazone, by activating PPAR-γ have shown pleiotropic effects in reducing vascular risk factors and atherosclerosis.
|
25521362 |
2014 |
|
Atherosclerosis
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Brachiocephalic arteries from TRAIL(-/-)ApoE(-/-) and ApoE(-/-) mice fed a high fat diet for 12 w demonstrated increased chondrocyte-like cells in atherosclerotic plaque, as well as increased aortic collagen II mRNA expression in TRAIL(-/-)ApoE(-/-) mice, with significant increases in calcification observed at 20 w. TRAIL(-/-)ApoE(-/-) aortas also had significantly elevated RANKL, BMP-2, IL-1β, and PPAR-γ expression at 12 w. Our data provides the first evidence that TRAIL deficiency results in accelerated cartilaginous metaplasia and calcification in atherosclerosis, and that TRAIL plays an important role in the regulation of RANKL and inflammatory markers mediating bone turn over in the vasculature.
|
24040204 |
2013 |
|
Atherosclerosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
In conclusion, the chalcone derivate AN07 has versatile therapeutic potential against atherosclerosis by acting as peroxisome proliferator-activated receptor gamma inducer, p44/42 mitogen-activated protein kinase inhibitor, and cell cycle blocker.
|
22157260 |
2012 |
|
Atherosclerosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
Adipocytokines such as tumor necrosis factor-alpha (TNF-α), C-reactive protein (CRP), adiponectin, leptin, resistin along with peroxisome proliferator activated receptor-γ (PPAR-γ) are important mediators in glucose homeostasis in association with CD36 and can be used as markers for T2DM and atherosclerosis.
|
21262584 |
2011 |
|
Atherosclerosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
Peroxisome proliferator-activated receptor gamma induces apoptosis and inhibits autophagy of human monocyte-derived macrophages via induction of cathepsin L: potential role in atherosclerosis.
|
21700710 |
2011 |
|
Atherosclerosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
For the first time we demonstrate that CRP modulates PPAR-gamma and its effector genes and reinforces the mechanistic link of CRP as a possible mediator in atherosclerosis and also advocate atorvastatin as a therapeutic modality.
|
20682172 |
2010 |
|
Atherosclerosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
Nifedipine induces peroxisome proliferator-activated receptor-gamma activation in macrophages and suppresses the progression of atherosclerosis in apolipoprotein E-deficient mice.
|
20508203 |
2010 |
|
Atherosclerosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
In conclusion, TSPG could inhibit the maturation of DCs induced by oxidized-LDL which suggests beneficial effects on atherosclerosis and this effect was partly dependent on the PPARgamma pathway at least.
|
20362279 |
2010 |
|
Atherosclerosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
Chronic disorders, such as obesity, diabetes, inflammation, non-alcoholic fatty liver disease and atherosclerosis, are related to alterations in lipid and glucose metabolism, in which peroxisome proliferator-activated receptors (PPAR)α, PPARβ/δ and PPARγ are involved.
|
20842602 |
2010 |
|
Atherosclerosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
PPARδ may serve as a more potent therapeutic target than PPARγ in atherosclerosis or inflammatory therapy.
|
19395102 |
2010 |
|
Atherosclerosis
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Together, these results indicate that the stimulation of SR-B1 expression in the liver is mediated in part by activation of the PPAR-gamma and RXR, and raise the possibility that this stimulation using thiazolidinediones conditions provides a protective mechanism for accelerated atherosclerosis in diabetes mellitus.
|
19156545 |
2009 |
|
Atherosclerosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
Peroxisome proliferator-activated receptor gamma (PPAR gamma) is a nuclear receptor that has been suggested to play protective roles in the pathogenesis of diseases that are characterized by chronic inflammation, such as atherosclerosis.
|
18308193 |
2008 |
|
Atherosclerosis
|
0.500 |
PosttranslationalModification
|
disease |
LHGDN |
Homocysteine-mediated PPARalpha,gamma DNA methylation and its potential pathogenic mechanism in monocytes.
|
18004978 |
2008 |
|
Atherosclerosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
BACKGROUND Peroxisome proliferator-activated receptor gamma (PPARgamma) is involved mainly in adipocyte differentiation and has been suggested to play an important role in the pathogenesis of insulin resistance (IR) and atherosclerosis.
|
18362424 |
2008 |
|
Atherosclerosis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The interaction result for S(I) was replicated by the Insulin Resistance Atherosclerosis Family Study (P = 0.018) in their San Antonio sample (n = 484) where subjects with at least one PPARG2 Ala allele and homozygous for the HNF4A rs2144908 A allele had a 29% higher S(I) compared with individuals with at least one G allele.
|
18162503 |
2008 |
|
Atherosclerosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
The ongoing clinical use of fibrates, which activate PPARalpha, and thiazolidinediones, which activate PPARgamma, establishes these receptors as viable drug targets, whereas considerable in vitro animal model and human surrogate marker studies suggest that PPAR activation may limit inflammation and atherosclerosis.
|
17261671 |
2007 |
|
Atherosclerosis
|
0.500 |
Therapeutic
|
disease |
CTD_human |
[Rosiglitazone enhances the anti-atherosclerotic effects of peroxisome proliferator-activated receptor gamma1 gene transfer in apolipoprotein-knock out mice].
|
18269830 |
2007 |
|
Atherosclerosis
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Peroxisome proliferator-activated receptor gamma (PPARgamma) is a transcription factor implicated in the expression of proinflammatory cytokines in atheroma-associated cells, and the expression of proinflammatory cytokines, such as tumor necrosis factor alpha (TNF-alpha) and matrix metalloproteinases (MMPs), represents a critical step in atherogenesis and atherosclerosis.
|
17892998 |
2007 |